Thymectomy in XXXX with @entity1109 .

@entity1 @entity704 @entity4836 @entity1109 @entity1737 @entity8792 @entity6732 @entity934
Eighteen @entity1 with exclusively @entity1109 of @entity1737 were thymectomised. @entity704 , resistance to @entity4836 therapy or relapse following immunosuppressive therapy were taken as indications for surgery. The mean preoperative observation period before operation was 40 months, and after operation was 26 months. There was no operative or postoperative morbidity or mortality. @entity6732 were found in all @entity1 (in one case, @entity704 ; in four, persistent thymus; in 13, @entity8792 ). The histological abnormalities were identical to those found in generalised @entity1737 . This included the distribution of T-cell subtypes as identified by use of monoclonal antibodies. The severity of @entity1109 was rated using a score developed for this purpose. The score progressively declined after surgery to an average of 70% of its initial amount in 80% of @entity1 . Full remission occurred in three cases. No @entity1 developed generalized @entity1737 . Antibody titres against @entity934 receptors if elevated preoperatively also dropped following surgery, with one exception. Clear criteria for the expected therapeutic success of thymectomy could not be identified. Based on our results, and on the assumed significance of the thymus gland for pathogenesis, thymectomy should be considered in @entity1 with @entity1109 .
